Saving Lives Through Innovation
Chrysalis BioTherapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of treatments for serious respiratory disorders and acute radiation exposure
Our Innovative Solutions
TP508 Peptide Technology
The TP508 thrombin peptide is released locally following vascular injury to initiate cellular regenerative processes that lead to revascularization, stem cell activation, and tissue repair.
Radiation Therapy (Brain Cancer)
The TP508 Solution. Our novel peptide drug product, TP508, reduces RT-induced neural inflammation and restores neural stem cells in the hippocampus of the brain.
Respiratory Failure (ARDS)
Acute respiratory distress syndrome (ARDS) affects more than 3 million people each year globally and ~180,000 patients in the US, accounting for 10% of intensive care unit admissions, of which the mortality rate is ~30%.
Solution for Nuclear Radiation Exposure
A single TP508 injection 24 hours after a lethal dose of whole body radiation significantly increases survival and reduces delayed effects of radiation.
Chrysalis BioTherapeutics, Inc.
Chrysalis is pioneering the use of natural regenerative peptides to restore vascular function and activate normal stem cell populations where they exist in the body to accelerate tissue repair and prevent damaging effects of trauma, disease, ischemia, and radiation exposure
The Problem
The Solution
There is an urgent unmet clinical need for a drug to prevent mortality caused by acute respiratory distress syndrome (ARDS) from infection, inflammation, or traumatic injury. The immediate target indication for TP508 is to treat mild to moderate ARDS patients to reduce mortality and reverse systemic effects on lung, heart, brain and kidney.
TP508 Clinical Pipeline
Chrysalis is pioneering the use of natural peptide regenerative drugs to restore vascular function and activate normal stem cell populations where they exist in the body. Our lead product Chrysalin™ (TP508) has demonstrated potential for clinical benefit in human clinical trials and in preclinical studies for multiple clinical indications. Chrysalis has utilized non-dilutive funding to build a diverse pipeline with focus on preventing acute lung failure and mitigating effects of radiation.
The TP508 Nuclear Countermeasure Program funded by NIH and BARDA is being developed under the FDA Animal Rule program with potential approval as early as 2027.
It has become clear that Acute Respiratory Distress Syndrome (ARDS) is an endothelial vascular disease with vascular damage similar to that seen after radiation exposure. Chrysalis is developing TP508 to treat ARDS induced infection, inflammation, or traumatic injury. The FDA has approved Chrysalis IND application to proceed with Phase I human clinical trials.
Secondary indications for radiation therapy and neural recovery following traumatic brain injury are still in preclinical development.
INDICATION | Pre-Clinical Studies | IND Enabling Studies/cGMP Manufacturing | Phase 1/2 |
|---|---|---|---|